GPX4 and small cell lung carcinoma: Importantly, when analyzing SCLC patients with combined low expression of GPX4 and TXNRD1 mimicking combo treatment, we obtained a group of patients with a drastically improved median survival time of 43.5 months as compared to 16 months median survival in the high/high group (Fig. 6l).